Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: A prospective randomized study

Blood

Volumn 96, Issue 7, 2000, Pages 2391-2398

  Ruutu, Tapani ^a   Volin, Liisa ^a   Parkkali, Terttu ^a   Juvonen, Eeva ^a   Elonen, Erkki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AVASCULAR NECROSIS; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINGLE BLIND PROCEDURE; SURVIVAL RATE;

EID: 0034307364     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.7.2391     Document Type: Article

References (26)

1. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow Transplantation (EBMT)
2. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
3. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective randomized trial
4. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: Methotrexate/prednisone v cyclosporine A/prednisone
5. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: A randomized double-blind study in patients undergoing allogeneic marrow transplantation
6. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study
7. Allogeneic bone marrow transplantation with related donors other than HLA MLC-matched siblings, and the use of antithymocyte globulin, prednisone, and methotrexate for prophylaxis of graft-versus-host disease
8. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CDS-RTA Xomazyme-CD5) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation
9. Antipan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors
10. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
11. A prospective randomised trial of cyclosporine and methotrexate versus cyclosporine, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy
12. Graft-versus-host disease prophylaxis for matched unrelated donor bone marrow transplantation: Comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone
13. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group
14. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
15. Bone marrow transplantation
16. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients
17. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression
18. Equivalence of two effective GVHD prophylaxis regimens: Results of a prospective blinded randomized trial
19. A randomized trial comparing cyclosporine A 1 vs 5 mg/kg/day in allogeneic bone marrow transplantation
20. Methotrexate combined with cyclosporine A decreases graft-versus-host disease but increases leukemic relapse compared to monotherapy
21. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia
22. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia
23. Lung injuries associated with graft-versus-host reactions
24. Poor graft function associated with graft-versus-host disease after allogeneic bone marrow transplantation
25. The effect of GVHD on the hematopoietic system
26. How should corticosteroids be used in the treatment of acute GVHD?